Hepatitis C virus

Phase I

This study is currently recruiting participants.

The purpose of this study is to evaluate the safety, tolerability and immunogenicity of VGX-6150 as a second-line therapy in chronic hepatitis C patients.

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (VGX-6150-01).

VGX-6150-01

INO-8000/VGX-6150

For more information please go to the study protocol.



Hepatitis B virus

Phase I

This study is currently recruiting participants.

This study is an open-label study to evaluate the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding HBsAg and HBcAg) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electroporation (EP) in 126 (one hundred twenty six) HBeAg-positive patients previously treated with entecavir or tenofovir.

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, HBeAg+, Chronic Hepatitis B Patients.

HBV-001

INO-1800

 



HIV, clades A, C, and D

Phase I

This study is ongoing, but not recruiting participants.

The purpose of this study is to evaluate the safety of and immune response to a primate vaccination with a synthetic DNA vaccine for the HIV subtypes A,C and D followed by a boost with a viral vector based HIV vaccine.

A Study of the Safety and Immunogenicity of PENNVAX®-G DNA (Env & Gag) Administered by Intramuscular Biojector 2000 or CELLECTRA® Intramuscular Electroporation Device Followed by MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) Boost in Healthy, HIV Uninfected Adults

RV 262

PENNVAX®-G

For more information please go to the study protocol.